cdk9in2

CDK9-IN-2 is a specific CDK9 inhibitor with an IC50 of 5 nM in the A2058 skin cell line (72 hours) and 7 nM in the H929 multiple myeloma cell line (72 hours).

EGFR/HER2/CDK9-IN-2 are potent inhibitors of EGFR/HER2/CDK9, and they exhibited significant antitumor effects with IC50s of 145.35, 129.07 and 117.13 nM, respectively.

CDK9-IN-23 (Example 4) is a highly potent CDK9 inhibitor with an IC50 value below 20 nM [1].

CDK9-IN-24 (compound 21a) is a potent and selective CDK9 inhibitor that significantly inhibits tumor proliferation, impedes cell growth, and triggers apoptosis via downregulation of Mcl-1 and c-Myc, making it valuable for acute myeloid leukemia research [1].

CDK9-IN-27 (Compound 6a), a CDK9 inhibitor with an IC50 of 0.424 μM, induces apoptosis and S-phase cell cycle arrest. It exhibits cytotoxicity against HepG2, HCT-116, and MCF-7 cell lines, with IC50 values ranging from 10.31 to 40.34 μM, rendering it applicable in cancer research [1].

CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 μM. It also exhibits affinity for the main protease of COVID-19 and demonstrates antiviral activity against human coronavirus 229E, with an IC50 of 63.28 μM [1].

CDK9-IN-26, also known as compound 1, is a potent inhibitor of Cyclin-Dependent Kinase 9 (CDK9) with an IC50 value of 0.18 μM.[1]

PROTAC CDK9/CycT1 Degrader-1 (compounds 10), a potent CDK9 inhibitor and target protein ligand for PROTAC synthesis, exhibits substantial anti-proliferative activity in solid tumors [1], making it instrumental in the targeted degradation of CDK9/CycT1.

CDK9-IN-29 (compound Z11) is a potent CDK9 inhibitor, demonstrating high kinase selectivity with an IC50 of 3.20 nM, effectively hindering cell proliferation and inducing apoptosis [1].